Biogen Inc.
BIIB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000875045
No open-market purchases or sales by Biogen Inc. insiders were filed in the last 90 days; 1,062 institutions reported holding it in 13F filings for Q3 2026, worth $31.5B in total; Maverick Capital is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 29, 2026, 1:12 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 14, 2026 | Feb 12, 2025 | Feb 13, 2024 | Feb 15, 2023 | Feb 3, 2022 |
| Revenue | $9.89B | $9.68B | $9.84B | $10.2B | $11.0B |
| Cost of revenue | $2.40B | $2.31B | $2.53B | $2.28B | $2.11B |
| Research and development | $1.78B | $2.04B | $2.46B | $2.23B | $2.50B |
| Selling, general and administrative | $2.43B | $2.40B | $2.55B | $2.40B | $2.67B |
| Operating income | – | – | – | – | $2.84B |
| Interest expense | $267.5M | $250.3M | $246.9M | $246.6M | $253.6M |
| Income tax | $263.6M | $273.8M | $135.3M | $632.8M | $52.5M |
| Net income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B |
| EPS, basic | $8.83 | $11.21 | $8.02 | $20.96 | $10.44 |
| EPS, diluted | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 |
| Weighted shares, basic | 146.5M | 145.6M | 144.7M | 145.3M | 149.1M |
| Weighted shares, diluted | 147.1M | 145.9M | 145.6M | 146.0M | 149.6M |
| Margins and growth | |||||
| Operating margin | – | – | – | – | 25.9% |
| Net margin | 13.1% | 16.9% | 11.8% | 29.9% | 14.2% |
| Revenue growth, year over year | +2.2% | −1.6% | −3.3% | −7.4% | −18.3% |
| Net income growth, year over year | −20.8% | +40.6% | −61.9% | +95.8% | −61.1% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 14, 2026 | Feb 12, 2025 | Feb 13, 2024 | Feb 15, 2023 | Feb 3, 2022 |
| Accounts receivable | $1.34B | $1.40B | $1.66B | $1.71B | $1.55B |
| Inventory | $2.17B | $2.46B | $2.53B | $1.34B | $1.35B |
| Total current assets | $8.97B | $7.46B | $6.86B | $9.79B | $7.86B |
| Property, plant and equipment | $3.06B | $3.18B | $3.31B | $3.30B | $3.42B |
| Goodwill | $6.49B | $6.48B | $6.22B | $5.75B | $5.76B |
| Intangible assets | $9.18B | $9.69B | $8.36B | $1.85B | $2.22B |
| Total assets | $29.4B | $28.0B | $26.8B | $24.6B | $23.9B |
| Accounts payable | $432.0M | $424.2M | $403.3M | $491.5M | $589.2M |
| Short-term debt | $0 | $1.75B | $150.0M | $0 | $999.1M |
| Total current liabilities | $3.35B | $5.53B | $3.43B | $3.27B | $4.30B |
| Long-term debt | $6.29B | $6.30B | $6.94B | $6.28B | $6.27B |
| Total liabilities | $11.2B | $11.3B | $12.0B | $11.2B | $12.9B |
| Shareholders' equity | $18.3B | $16.7B | $14.8B | $13.4B | $11.0B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 14, 2026 | Feb 12, 2025 | Feb 13, 2024 | Feb 15, 2023 | Feb 3, 2022 |
| Operating cash flow | $2.20B | $2.88B | $1.55B | $1.38B | $3.64B |
| Capital expenditures | $153.8M | $153.7M | $277.0M | $240.3M | $258.1M |
| Free cash flow | $2.05B | $2.72B | $1.27B | $1.14B | $3.38B |
| Depreciation and amortization | $779.9M | $673.2M | $494.8M | $518.4M | $487.7M |
| Stock-based compensation | $290.8M | $291.2M | $264.2M | $254.1M | $238.6M |
| Share buybacks | – | $0 | $0 | $750.0M | $1.80B |
| Investing cash flow | -$1.37B | -$799.2M | -$4.10B | $1.58B | -$563.7M |
| Financing cash flow | -$301.9M | -$683.5M | $149.3M | -$1.75B | -$2.09B |
| Ratio | |||||
| Stock-based compensation, % of revenue | 2.9% | 3.0% | 2.7% | 2.5% | 2.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 26, 2026 | 147.8M | +0.8% | SEC |
| Jul 27, 2026 | 147.8M | +0.8% | SEC |
| Apr 27, 2026 | 147.6M | +0.8% | SEC |
| Feb 4, 2026 | 146.8M | +0.3% | SEC |
| Oct 29, 2025 | 146.7M | +0.7% | SEC |
| Jul 29, 2025 | 146.6M | +0.7% | SEC |
| Apr 30, 2025 | 146.5M | +0.6% | SEC |
| Feb 11, 2025 | 146.4M | +0.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.